Testing of Homocysteine Metabolism-Related Conditions
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - M2141 alerts
Get alerted when Policy AHS - M2141 changes without checking for updates manually.
Monitor payer policy activity
Coverage policy for laboratory testing used to detect and monitor homocystinuria and related homocysteine/metabolic disorders, including newborn screening, diagnostic plasma/dried blood spot testing, and monitoring of confirmed CBS deficiency; applies to providers submitting claims to Medical Mutual - Ohio.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Covered Indications
Covered when any of the following apply:
[[chunk 3]]
[[chunk 3]]
[[chunk 3]]
inv-02: Guideline-based coverage and testing recommendations
Guideline-based testing recommendations cited in policy
E-HOD strong recommendation; quality moderate
E-HOD recommendation; specificity increased by tHcy second-tier
Grade B-C; gold standard: cultured fibroblasts
E-HOD recommendations
Targets proposed by E-HOD/Morris et al.
Analytical comparisons in the literature indicate that plasma assays generally perform better than dried blood spot (DBS) methods for methylmalonic acid (MMA) and total homocysteine (tHcy), although DBS tHcy may offer advantages for specimen stability. A UPLC‑MS/MS comparison found strong correlation between plasma and DBS tHcy measurements and concluded DBS can be an acceptable alternative when plasma processing is not feasible, but overall analytical performance favored plasma testing. Clinical workflows should favor plasma tHcy when available, with DBS reserved for settings where prompt plasma processing is not possible.
The policy editorial changes removed the pyridoxine (vitamin B6) challenge test from the laboratory coverage scope because it is classified as a medical procedure rather than a laboratory test. The revision explicitly removed the prior coverage statement and the associated CPT code (84207) from the laboratory policy; providers seeking pyridoxine challenge testing should pursue it as a clinical/medical procedure outside the laboratory test coverage rules.
Guideline guidance from E‑HOD strongly recommends measuring total homocysteine (tHcy) in blood rather than measuring free homocysteine. Total homocysteine is the recommended frontline laboratory measurement for suspected remethylation and CBS deficiency and already includes free and bound forms of homocysteine, making separate free Hcy testing unnecessary.
Measurement of free homocysteine is discouraged because it is detectable only at relatively high tHcy concentrations and is reported to have poor sensitivity and limited reproducibility; therefore it is not recommended as a substitute for total homocysteine testing.
Covered Indications and Use Cases
inv-24: Newborn screening for classic homocystinuria (CBS deficiency) and screening for hypermethioninemia; use of Met/Phe ratio as first-tier with tHcy as second-tier
Newborn screening strategies and covered newborn indications
E-HOD and ACMG recommend Met and Met/Phe first-tier ([[chunk 18]])
tHcy as second-tier increases specificity ([[chunk 18]])
Covered follow-up per policy ([[chunk 3]])
inv-25: Diagnostic testing for suspected remethylation disorders or CBS deficiency — prompt plasma tHcy and pre-treatment specimens
Diagnostic testing for suspected disorders — prompt testing and pre-treatment specimen collection
E-HOD strong recommendation; policy references ([[chunk 19]], [[chunk 3]])
Ensure samples collected prior to therapy per guidelines ([[chunk 19]])
Pre-analytic handling recommended ([[chunk 19]])
inv-26: Monitoring therapy in confirmed CBS deficiency — plasma total homocysteine testing meets coverage criteria for monitoring in adults
Monitoring criteria for confirmed CBS deficiency in adults
Policy states plasma tHcy testing meets coverage criteria for adults ([[chunk 3]])
Target ranges referenced in guidelines and clinical utility ([[chunk 21]], [[chunk 12]])
inv-27: Suspected remethylation disorders and CBS deficiency; newborn screening recommendations — tHcy frontline; Met/Met:Phe first-tier with tHcy second-tier
Recommended frontline testing and newborn screening approach for suspected remethylation disorders and CBS deficiency
E-HOD recommendations ([[chunk 19]])
E-HOD guidance ([[chunk 18]], [[chunk 20]])
Gold standard described by E-HOD ([[chunk 20]])
Coding and Diagnostic Thresholds
| No codes listed |
Provider Actions and Billing Notes
Benefit verification required
Verify member benefits and any applicable requirements (including prior authorization, coverage limits, and medical necessity criteria) before submitting testing requests. Coverage is benefit-dependent — coverage determinations are made based on the individual's plan at the time of service; Medicare and Medicaid members are subject to applicable government rules.
- Benefit verification required at time of request
- Medicare/Medicaid per applicable regulations
Procedure codes and payer review
Providers should follow payer billing and prior authorization processes for the CPT/HCPCS codes associated with homocysteine and related testing. Confirm coding and medical necessity with the payer; some codes may require additional documentation.
Government policy precedence
If a conflict exists between this policy and any applicable government policy (e.g., LCD, NCD, or state Medicaid), the government policy will take precedence and will be used to make coverage determinations.
- Government (LCD/NCD/state Medicaid) policy supersedes when in conflict
- Check CMS and state Medicaid sites for current guidance
Specimen handling and pre-treatment testing
When total homocysteine (tHcy) is elevated, obtain plasma and urine samples for MMA, methionine, folate, and vitamin B12 prior to initiating treatment. These pre-treatment tests support differential diagnosis between remethylation disorders and CBS deficiency and are recommended by guideline bodies.
- Obtain plasma and urine MMA, methionine, folate, and vitamin B12 before treatment when tHcy is high
- Use tHcy and Met measurements together to help distinguish CBS deficiency from other disorders
Pre-analytic and pre-treatment sampling
Collect and handle samples per guideline recommendations to ensure valid tHcy results: centrifuge blood specimens within one hour of collection and keep them refrigerated (about 4°C) or freeze until analysis; maintain cold chain during transport. Use total homocysteine assays (immunoassay or chromatographic methods); do not substitute free homocysteine.
- Centrifuge within one hour and keep samples at 4°C or frozen until analysis
- Use immunoassays or chromatographic methods for tHcy; do not measure free homocysteine instead of total homocysteine
- Dried blood spot tHcy measurement acceptable if plasma processing is not possible
Benefit-dependent coverage
Coverage is dependent on the member's benefit at the time of request; verify eligibility, plan exclusions, and any program-specific rules (Medicare/Medicaid) prior to testing.
- Benefit-dependent coverage — confirm member benefits at time of request
- Medicare/Medicaid governed by applicable LCD/NCD and state Medicaid rules
Ordering and Specimen Requirements
Ordering: follow specimen handling and pre-treatment sampling guidance
No specific ordering-provider restrictions are stated in this policy; however, ensure proper specimen handling and pre-treatment sampling per guidance when ordering tHcy and related tests.
- Ensure plasma/urine samples for confirmatory testing are obtained before treatment when indicated
- Follow prompt processing and cold-chain requirements for tHcy specimens
tHcy pre-analytic handling: centrifuge quickly and keep cold or frozen
For total homocysteine testing, centrifuge the blood sample within one hour of collection and keep the plasma at 4°C or frozen until analysis; immunoassays or chromatographic methods are acceptable for tHcy measurement.
- Centrifuge within one hour
- Store at 4°C or freeze until analysis
- Use validated immunoassay or chromatographic methods
Frequency and Monitoring Limits
Not Covered / Exclusions
Free homocysteine testing in place of total homocysteine (tHcy) is not recommended. E‑HOD issues a strong recommendation against measuring free homocysteine as a replacement for tHcy because free Hcy lacks sensitivity and reproducibility compared with total plasma homocysteine.
The pyridoxine (B6) challenge test has been removed from the laboratory policy because it is considered a medical procedure rather than a laboratory test. This change eliminates the prior laboratory coverage statement for the pyridoxine challenge and removes CPT code 84207 from the policy's procedure code list; providers should classify this evaluation as a clinical/medical procedure outside the laboratory testing coverage rules.
Background
Homocystinuria is an inherited metabolic disorder most commonly caused by deficiency of cystathionine β‑synthase (CBS). Classic CBS deficiency produces markedly elevated total homocysteine (tHcy) and often increased methionine (Met). Typical diagnostic biochemical features are tHcy <15 µmol/L in controls, neonates with homocystinuria often >50 µmol/L, and untreated older individuals frequently >100 µmol/L. Measurement of plasma tHcy is the frontline laboratory test for diagnosis and monitoring; when tHcy is elevated, additional pre‑treatment testing (plasma and urine methylmalonic acid, plasma methionine, folate and vitamin B12) should be obtained and plasma processing should occur promptly to preserve specimen integrity.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.